-
Exclusive: Egalet CEO Talks Drug Approvals, 21st Century Cures Act And Winning The War On Opioid Abuse
Thursday, January 19, 2017 - 9:37am | 1104Read More...Egalet Corp (NASDAQ: EGLT) was surely one of the most watched biotechs of the fourth quarter of 2016. After the company announced the Food and Drug Administration would miss its PDUFA decision date for Egalet’s opioid-based pain medication ARYMO ER, investors waited impatiently for news of a...
-
Egalet Reports Q3 Results, Offers ARYMO ER Updates
Friday, November 4, 2016 - 7:24am | 118Read More...Egalet Corp (NASDAQ: EGLT) lost $1.10 per share in its third quarter and missed estimates by $0.20 per share. Revenue of $4.7 million beat by $0.1 million. Company highlighted FDA Advisory Committee's recommended approval of ARYMO ER during the quarter. Company also highlighted...
